Company Profile
Humanwell Healthcare (Group) researches, develops, produces, and sells pharmaceutical products in China and globally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia.
Its portfolio also includes remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia, hydromorphone hydrochloride injection for patients who require opioid analgesia, nabuphine hydrochloride injection for use as an analgesic for anesthesia induction, alfentanil hydrochloride injection, a narcotic analgesic, remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery, and mifepristone preparations for pregnancy prevention or termination, as well as zuka wood particles for colds.
Its portfolio also includes compound muniziqi granules to treat skin and gynecologicalconditions, urokinase injection for thromboembolic diseases, and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals.
Additionally, it offers progesterone, estrogen, androgen, cortical hormone, and API products. Its portfolio also includes steroid hormone products, natural plant-based medicines, central nervous system drugs, animal medicine, narcotics, and Uyghur medicine products. It also is involved in the production of veterinary drugs, feed additive, medical devices, and agricultural products.
Its portfolio also includes technical development, exchange, and transfer, leasing of medical devices, conference, exhibition, inspection, and testing, property management, pharmaceutical contract manufacturing, cleaning, washing, and disinfection, warehousing and logistics, investment management and consulting services, and production of health foods. in March 2013.
Humanwell Healthcare (Group) Co.,Ltd. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. was founded in 1988 and is based in Wuhan, China.